4.7 Article

Chronic Δ9-tetrahydrocannabinol treatment in rhesus monkeys: differential tolerance and cross-tolerance among cannabinoids

期刊

BRITISH JOURNAL OF PHARMACOLOGY
卷 162, 期 5, 页码 1060-1073

出版社

WILEY-BLACKWELL PUBLISHING, INC
DOI: 10.1111/j.1476-5381.2010.01116.x

关键词

cannabinoid; cross-tolerance; drug discrimination; efficacy; fixed ratio responding; rhesus monkey; tolerance

资金

  1. U.S. Public Health Service, National Institutes of Health, National Institute on Drug Abuse [R01-DA19222, R01-DA26781]

向作者/读者索取更多资源

BACKGROUND AND PURPOSE The extent to which behavioural effects vary as a function of CB(1) receptor agonist efficacy is not clear. These studies tested the hypothesis that cannabinoid tolerance and cross-tolerance depend upon the CB(1) agonist efficacy of drugs to which tolerance/cross-tolerance develops. EXPERIMENTAL APPROACH Sensitivity to cannabinoids, including the cannabinoid antagonist rimonabant, low efficacy agonist Delta 9-tetrahydrocannabinol (Delta 9-THC), and high efficacy agonists CP 55940 and WIN 55212-2, was determined before and after chronic Delta 9-THC treatment in rhesus monkeys. Two measures of behavioural effect were assessed: effects of drugs to decrease fixed ratio responding for food presentation and stimulus-shock termination and discriminative stimulus effects in monkeys discriminating Delta 9-THC (0.1 mg center dot kg-1, i.v.). KEY RESULTS Delta 9-THC decreased responding for both food presentation and stimulus-shock termination; these effects were antagonized by the CB(1) antagonist rimonabant. Chronic Delta 9-THC (1 mg center dot kg-1 per 12 h, s.c.) resulted in tolerance to the rate-decreasing effects of Delta 9-THC and cross-tolerance to CP 55940 and WIN 55212-2; however, cross-tolerance was less than tolerance. Chronic Delta 9-THC increased sensitivity to rimonabant without changing sensitivity to the non-cannabinoids midazolam and ketamine. In monkeys discriminating Delta 9-THC (0.1 mg center dot kg-1, i.v.), both CP 55940 and WIN 55212-2 produced high levels of drug-lever responding. Chronic Delta 9-THC (1 mg center dot kg-1 per day, s.c.) decreased sensitivity to Delta 9-THC without producing cross-tolerance to CP 55940 or WIN 55212-2. CONCLUSIONS AND IMPLICATIONS In Delta 9-THC-treated monkeys, the magnitude of tolerance and cross-tolerance to other CB(1) receptor agonists varied inversely with agonist efficacy, suggesting that CB(1) agonist efficacy is an important determinant of behavioural effects.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据